Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer

Eichler, 2010, EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer, Neuro Oncol, 12, 1193, 10.1093/neuonc/noq076 Chamberlain, 2010, Leptomeningeal metastasis, Semin Neurol, 30, 236, 10.1055/s-0030-1255220 Nagpal, 2012, Treatment of leptomeningeal spread of NSCLC: a continuing challenge, Curr Treat Options Oncol, 13, 491, 10.1007/s11864-012-0206-4 Morris, 2012, Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy, J Thorac Oncol, 7, 382, 10.1097/JTO.0b013e3182398e4f Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938 Park, 2012, Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era, Lung Cancer, 76, 387, 10.1016/j.lungcan.2011.11.022 Yi, 2009, Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI, Lung Cancer, 65, 80, 10.1016/j.lungcan.2008.10.016 Umemura, 2012, Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group, Lung Cancer, 77, 134, 10.1016/j.lungcan.2012.03.002 Jackman, 2006, Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib, J Clin Oncol, 24, 4517, 10.1200/JCO.2006.06.6126 Togashi, 2012, Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer, Cancer Chemother Pharmacol, 70, 399, 10.1007/s00280-012-1929-4 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Han, 2005, Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib, J Clin Oncol, 23, 2493, 10.1200/JCO.2005.01.388 Van Horn, 2012, Neoplastic meningitis, J Support Oncol, 10, 45, 10.1016/j.suponc.2011.06.002 Omuro, 2005, High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib, Cancer, 103, 2344, 10.1002/cncr.21033 McKillop, 2006, Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition, Xenobiotica, 36, 29, 10.1080/00498250500523253 Katayama, 2009, Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib, J Thorac Oncol, 4, 1415, 10.1097/JTO.0b013e3181b62572 Glantz, 1998, High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?, J Clin Oncol, 16, 1561, 10.1200/JCO.1998.16.4.1561 Grommes, 2011, “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer, Neuro Oncol, 13, 1364, 10.1093/neuonc/nor121 Dhruva, 2009, Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib, J Clin Oncol, 27, e31, 10.1200/JCO.2008.21.0963 Yamamoto, 2008, Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors, Cancer Chemother Pharmacol, 61, 489, 10.1007/s00280-007-0494-8 Fukuoka, 2003, Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected], J Clin Oncol, 21, 2237, 10.1200/JCO.2003.10.038